BiotechTube

Aldara (Imiquimod)

Phase 3Completed
0 watching 0 views this week📈 Rising
74
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Actinic Keratosis

Conditions

Actinic Keratosis

Trial Timeline

Feb 1, 2006 → Jan 1, 2007

NCT ID
NCT00294320

About Aldara (Imiquimod)

Aldara (Imiquimod) is a phase 3 stage product being developed by Viatris for Actinic Keratosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00294320. Target conditions include Actinic Keratosis.

Hype Score Breakdown

Clinical
27
Activity
18
Company
7
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT00294320Phase 3Completed

Competing Products

20 competing products in Actinic Keratosis

See all competitors
ProductCompanyStageHype Score
Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%Sun PharmaceuticalPhase 3
77
Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%Sun PharmaceuticalPhase 3
77
Diclofenac Sodium Gel 3% + Solaraze® (diclofenac sodium) Gel 3% + Vehicle Topical GelSun PharmaceuticalPhase 1
33
Imiquimod Topical Cream 3.75% + Zyclara® (imiquimod) Topical Cream 3.75% + Vehicle Topical CreamSun PharmaceuticalPhase 1
33
Imiquimod 5% manufactured by Taro + Aldara - Imiquimod 5% + Imiquimod Vehicle manufactured by TaroSun PharmaceuticalPhase 1
33
Investigational Treatment + Active comparatorNovartisPhase 2
52
KX01 ointment 1% + PlaceboPharmaEssentiaPhase 3
76
FluorouracilSanofiPhase 1/2
40
fluorouracil cream 0.5%SanofiApproved
84
Imiquimod + DiclofenacViatrisApproved
82
Imiquimod 5 % CreamViatrisPhase 2
49
ImiquimodViatrisPre-clinical
20
Imiquimod + DiclofenacViatrisApproved
82
Low dose DFD07 once daily + High dose DFD07 once daily + High dose DFD07 twice daily + Placebo twice dailyDr. Reddy's LaboratoriesPhase 2/3
62
Placebo Gel + LAS41005 + LAS106521AlmirallPhase 3
72
5-fluorouracil/salicylic acid + VehicleAlmirallPhase 3
72
50 mg of KX2-391 Ointment 1% + 50 mg of KX2-391 Ointment 1%AlmirallPhase 2
47
Tirbanibulin (Klisyri®) 10 mg/g ointment + Diclofenac Sodium 3% GelAlmirallApproved
80
KX2-391 Ointment 1% + PlaceboAlmirallPhase 3
72
Tirbanibulin 2.5 mg ointmentAlmirallApproved
80

Other Products from Viatris

Revefenacin + Tiotropium + Revefenacin Placebo + Tiotropium PlaceboApproved
82
PregabalinApproved
82
Imiquimod + DiclofenacApproved
82
gabapentin 600 mg + gabapentin 1200 mg + gabapentin 1800 mg + diazepam 20 mgApproved
82
Sulfamylon® For 5 % Topical Solution + Topical Antimicrobial/Antifungal MedicationsApproved
82